Johnson & Johnson JNJ Analyst Ratings

19 ratings from Wall Street analysts · latest analyst action Feb 10, 2026

Analyst Ratings
Buy Consensus target withheld — no analyst update in over 90 days showing 19 ratings
Latest analyst action Feb 10, 2026
JNJ
Upgrade
2026-01-28
Morgan Stanley
RatingOverweight
FromEqual-Weight
Target$262
From
Initiated
2025-11-13
Scotiabank
RatingSector Outperform
From
Target$230
From
Upgrade
2025-10-20
Daiwa Securities
RatingOutperform
FromNeutral
Target$203
From
Upgrade
2025-10-03
Wells Fargo
RatingOverweight
FromEqual Weight
Target$212
From
Upgrade
2025-09-23
Guggenheim
RatingBuy
FromNeutral
Target$206
From
Downgrade
2025-05-13
Leerink Partners
RatingMarket Perform
FromOutperform
Target$153
From
Resumed
2024-12-10
BofA Securities
RatingNeutral
From
Target$166
From
Initiated
2024-11-15
Wolfe Research
RatingOutperform
From
Target$190
From
Downgrade
2024-07-23
Daiwa Securities
RatingNeutral
FromOutperform
Target$150
From$160
Resumed
2024-05-30
Goldman
RatingNeutral
From
Target$160
From
Upgrade
2024-04-18
HSBC Securities
RatingBuy
FromHold
Target$170
From
Downgrade
2023-12-13
Wells Fargo
RatingEqual Weight
FromOverweight
Target$163
From$170
Upgrade
2023-12-01
UBS
RatingBuy
FromNeutral
Target$180
From$167
Initiated
2023-10-05
RBC Capital Mkts
RatingOutperform
From
Target$178
From
Initiated
2023-09-06
HSBC Securities
RatingHold
From
Target$175
From
Resumed
2023-05-30
Citigroup
RatingBuy
From
Target$185
From
Initiated
2023-03-29
UBS
RatingNeutral
From
Target$164
From
Initiated
2023-03-01
Guggenheim
RatingNeutral
From
Target$161
From
Initiated
2022-11-18
Credit Suisse
RatingNeutral
From
Target$170
From